GWGary V. Walker

Gary V. Walker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gary V. Walker has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial

    by Alexander D. Sherry, Cara Haymaker, Shuqi Wang, Suyu Liu, Tharakeswara K. Bathala, Marina N. Medina-Rosales, Aaron Seo, Kieko Hara, Jay Reddy, Stephen G. Chun, et al.

    PURPOSE: We tested the hypothesis that adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy improves progression-free survival (PFS) among patients with oligometastatic disease. METHODS: EXTEND was a multicenter randomized phase II trial. Patients with 1-5 metastases were randomly assigned to MDT + SOC versus SOC in one of the six baskets (breast, pancreas, kidney, two prostate baskets, and an other basket) with basket-specific stratification and powering. PFS, the primary end point, was prespecified in the per-protocol set within each basket, across all baskets, and across all baskets excluding the prostate baskets. Exploratory end points included circulating tumor DNA (ctDNA) and immune profiling. RESULTS: From 2018 through 2023, 521 patients were screened, 350 were randomly assigned, and 334 were analyzed per protocol (MDT + SOC, n = 166; SOC, n = 168). Radiotherapy was used as MDT for 98% of metastases (370/379). Overall, after a median follow-up of 53 months, PFS was improved with MDT + SOC (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.72], P < .001). Similarly, PFS was improved when excluding the prostate baskets (HR, 0.60 [95% CI, 0.40 to 0.89]). Within each basket, PFS superiority was identified for the pancreas, prostate, and other baskets, whereas the breast and kidney baskets were inconclusive. At enrollment, detectable ctDNA correlated with shorter PFS and survival; by contrast, ctDNA clearance 3 months postenrollment correlated with improved survival. MDT + SOC-induced systemic immune activation was most pronounced among baskets demonstrating PFS superiority. CONCLUSION: The phase II EXTEND trial supports the addition of MDT to SOC for oligometastatic disease. Histology-specific efficacy signals were identified for phase III testing. Translational insights suggest the potential for optimizing the definition of oligometastasis using ctDNA and point to systemic immune responses as a possible mechanism of benefit from MDT.


  • Factors Associated With Image-Guided Radiation Therapy Image Rejection in a Multisite Institution

    by Michael K. Rooney, Blake Traube, Mohammed Khan, Rachit Kumar, Gary V. Walker

    Nonclinical factors and cognitive biases have been shown to significantly affect clinical decision making. In this study, we aimed to identify clinical and environmental factors that might influence the decision to approve or reject image-guided radiation therapy (IGRT) images in a large multisite institution. We identified all IGRT image approval and rejection decisions recorded within an electronic imaging system from July 1, 2016, to June 30, 2018. For each decision, we tabulated the following parameters: the attending physician of the patient, the physician reviewing the image, total images reviewed by the physician that day, time of day, day of week, treatment site, and imaging modality (kilovoltage or cone beam computed tomography [CBCT]). We created a binary multivariable logistic regression model to identify factors associated with IGRT image rejection. Overall, of 51,797 total image records evaluated, 881 (1.70%) were rejected and 50,916 (98.30%) were approved. Univariable analysis revealed that images reviewed by physicians with high rejection rates (odds ratio [OR], 3.16; P < .001) and by physicians reviewing fewer IGRT images (OR, 0.99; P = .024), images from various anatomic sites (particularly skin, breast, and head and neck), and CBCT imaging compared with kilovoltage imaging (OR, 1.49; P < .001) were associated with the increased rate of rejection. On multivariable analysis, images reviewed by physicians with high rejection rates (OR, 3.28; P < .001), images from specific anatomic sites including breast (P < .001), and CBCT imaging (P < .001) persisted as independent predictors of image rejection. These data provide important insight into the clinical, cognitive, and environmental factors that might influence the routine clinical decision of IGRT image approval. Recognition of these factors may not only improve the quality of individual decisions but also identify opportunities for systems-based quality improvement in IGRT.


  • PSA: Declining utilization of prostate brachytherapy

    by Lauren Andring, Alison Yoder, Todd Pezzi, Chad Tang, Rachit Kumar, Usama Mahmood, Gary V. Walker


  • Open Access

    Development of a Natural Language Processing Tool to Extract Radiation Treatment Sites

    by Gary Walker, Ergin Soysal, Hua Xu

    Currently, radiation oncology-specific electronic medical records (EMRs) allow providers to input the radiation treatment site using free text. The purpose of this study is to develop a natural language processing (NLP) tool to extract encoded data from radiation treatment sites in an EMR. Treatment sites were extracted from all patients who completed treatment in our department from April 1, 2011, to April 30, 2013. A system was designed to extract the Unified Medical Language System (UMLS) concept codes using a sample of 11,018 unique site names from 31118 radiation therapy (RT) sites. Among those, 5500 unique site name strings that constitute approximately half of the sample were spared as a test set to evaluate the final system. A dictionary and calculated n-gram statistics using UMLS concepts from related semantic types were combined with manually encoded data. There was an average of 2.2 sites per patient. Prior to extraction, the 20 most common unique treatment sites were used 4215 times (38.3%). The most common treatment site was whole brain RT, which was entered using 27 distinct terms for a total of 1063 times. The customized NLP solution displayed great gains as compared to other systems, with a recall of 0.99 and a precision of 0.99. A customized NLP tool was extracting encoded data from radiation treatment sites in an EMR with great accuracy. This can be integrated into a repository of demographic, genomic, treatment, and outcome data to advance personalized oncologic care.


  • Provider variability in intensity modulated radiation therapy utilization among Medicare beneficiaries in the United States

    by Stephen R. Grant, Benjamin D. Smith, Anna O. Likhacheva, Shervin M. Shirvani, David B. Rosen, B. Ashleigh Guadagnolo, Dean A. Shumway, Emma B. Holliday, Daniel Chamberlain, Gary V. Walker


  • The great esophageal escape: A case of extreme esophageal interfraction motion during neoadjuvant chemoradiation therapy

    by Stephen R. Grant, Chelsea M. Page, Irma Diaz, Stephen Bush, Tomasz Bista, Lehendrick M. Turner, Gary V. Walker


  • Palliation or Prolongation? The Impact of a Peer-Review Intervention on Shortening Radiotherapy Schedules for Bone Metastases

    by Gary V. Walker, Shervin M. Shirvani, Yerko Borghero, Matthew D. Callister, Daniel D. Chamberlain, Emily J. Grade, Mohamed K. Khan, Rachit Kumar, Jeffrey G. Richmond, Terence J. Roberts, et al.

    Purpose: Shorter fractionation radiation regimens for palliation of bone metastases result in lower financial and social costs for patients and their caregivers and have similar efficacy as longer fractionation schedules, although practice patterns in the United States show poor adoption. We investigated whether prospective peer review can increase use of shorter fractionation schedules. Methods: In June 2016, our practice mandated peer review of total dose and fractionation for all patients receiving palliative treatment during our weekly chart rounds. We used descriptive statistics and Fisher’s exact test to compare lengths of treatment of uncomplicated bone metastases before and after implementation of the peer review process. Results: Between July 2015 and December 2016, a total of 242 palliative treatment courses were delivered, including 105 courses before the peer review intervention and 137 after the intervention. We observed greater adoption of shorter fractionation regimens after the intervention. The use of 8 Gy in one fraction increased from 2.8% to 13.9% of cases postadoption. Likewise, the use of 20 Gy in five fractions increased from 25.7% to 32.8%. The use of 30 Gy in 10 fractions decreased from 55.2% to 47.4% ( P = .002), and the use of ≥ 11 fractions decreased from 16.2% before the intervention to 5.8% after ( P = .006). Conclusion: Prospective peer review of palliative regimens for bone metastases can lead to greater adoption of shorter palliative fractionation schedules in daily practice, in accordance with national guidelines. This simple intervention may therefore benefit patients and their caregivers as well as provide value to the health care system.


  • Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

    by Rachit Kumar, Gary Walker, Lauren Rosati, Sweet Ping Ng, Joseph Herman

  • Development of a Comprehensive Clinical Radiation Oncology Resident Didactic Curriculum

    by Emma B. Holliday, Cameron W. Swanick, Sarah A. McAvoy, Gary V. Walker, Christopher H. Crane, Anita Mahajan, Prajnan Das